Trusted medical expertise in seconds.

Access 1,000+ clinical and preclinical articles. Find answers fast with the high-powered search feature and clinical tools.

Try free for 5 days
Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer.

Systemic sclerosis

Last updated: February 3, 2021

Summarytoggle arrow icon

Systemic sclerosis (SSc) is a chronic disease caused by abnormal growth of connective tissue, which leads to diffuse thickening and hardening of the skin and often the inner organs. SSc is categorized into limited SSc and diffuse SSc. The more common, limited form of SSc begins with sclerosis of the fingers, hands, and face, which then progresses to the center of the body. Limited SSc is often associated with symptoms of CREST syndrome (calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) and may be followed by internal organ involvement as the disease progresses. Diffuse SSc is less common but more aggressive, with early organ system involvement that may be life-threatening if damage to the heart, lungs, or kidneys occurs. Treatment is symptomatic and based on the extent of skin and organ system involvement. In the case of diffuse inflammation of the skin and/or organs, immunosuppressive drugs (e.g., methotrexate) should be administered. The prognosis varies depending on which organs are involved, with pulmonary arterial hypertension, interstitial lung disease, and cardiac disease significantly increasing the mortality rate.

Epidemiological data refers to the US, unless otherwise specified.

The pathophysiology of SSc is not completely understood, but several factors play role in the development of the disease.

References:[4]

Common symptoms

Limited cutaneous systemic sclerosis

Diffuse cutaneous systemic sclerosis

References:[6][7][8][9][10][11][12][13]

References:[14][15]

Mixed connective tissue disease (MCTD, Sharp syndrome)

References:[16]

The differential diagnoses listed here are not exhaustive.

Treatment focuses on organ-specific, symptomatic therapy. In the case of diffuse cutaneous disease or severe organ involvement, immunosuppressive therapy is indicated.

  1. Barnes J, Mayes MD. Epidemiology of systemic sclerosis. Curr Opin Rheumatol. 2012; 24 (2): p.165-170. doi: 10.1097/bor.0b013e32834ff2e8 . | Open in Read by QxMD
  2. Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clinical Epidemiology. 2019; Volume 11 : p.257-273. doi: 10.2147/clep.s191418 . | Open in Read by QxMD
  3. Alba MA, Velasco C, Simeón CP, et al. Early- versus Late-Onset Systemic Sclerosis. Medicine. 2014; 93 (2): p.73-81. doi: 10.1097/md.0000000000000018 . | Open in Read by QxMD
  4. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018; 17 (9): p.882-889. doi: 10.1016/j.autrev.2018.03.012 . | Open in Read by QxMD
  5. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  6. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. http://dx.doi.org/10.1093/rheumatology/kel280. Updated: October 1, 2006. Accessed: April 4, 2017.
  7. Varga J. Overview of the Clinical Manifestations of Systemic Sclerosis (Scleroderma) in Adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/overview-of-the-clinical-manifestations-of-systemic-sclerosis-scleroderma-in-adults.Last updated: January 6, 2017. Accessed: April 13, 2017.
  8. Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology. 2016; 56 (1): p.14-25. doi: 10.1093/rheumatology/kew047 . | Open in Read by QxMD
  9. Ficalora RD. Mayo Clinic Internal Medicine Board Review. Oxford University Press ; 2013
  10. Telangiectasia. https://www.dermnetnz.org/topics/telangiectasia. Updated: January 1, 2014. Accessed: December 23, 2017.
  11. Singh A, Ambujam S, Varghese A, Vishranth SP, Sadanandan N. Salt-and-pepper appearance: A cutaneous clue for the diagnosis of systemic sclerosis. Indian J Dermatol. 2012; 57 (5): p.412-3. doi: 10.4103/0019-5154.100512 . | Open in Read by QxMD
  12. Giberson M, Brassard A. Salt-and-pepper skin changes. N Engl J Med. 2017; 377 (2): p.173-173. doi: 10.1056/nejmicm1610737 . | Open in Read by QxMD
  13. Systemic Sclerosis. https://www.dermnetnz.org/topics/systemic-sclerosis/. Updated: January 1, 2018. Accessed: April 2, 2018.
  14. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003; 5 (2): p.80-93.
  15. Bennett RM. Clinical Manifestations of Mixed Connective Tissue Disease. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/clinical-manifestations-of-mixed-connective-tissue-disease.Last updated: December 21, 2016. Accessed: April 13, 2017.
  16. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol. 2015; 6 : p.272. doi: 10.3389/fimmu.2015.00272 . | Open in Read by QxMD